Cathay Biotech Inc.
688065.SS · SHH
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | CN¥874 | CN¥895 | CN¥776 | CN¥743 |
| % Growth | -2.3% | 15.4% | 4.4% | – |
| Cost of Goods Sold | CN¥555 | CN¥648 | CN¥515 | CN¥620 |
| Gross Profit | CN¥319 | CN¥247 | CN¥261 | CN¥123 |
| % Margin | 36.5% | 27.6% | 33.6% | 16.6% |
| R&D Expenses | CN¥55 | CN¥63 | CN¥61 | CN¥65 |
| G&A Expenses | CN¥0 | CN¥48 | CN¥43 | CN¥36 |
| SG&A Expenses | CN¥68 | CN¥64 | CN¥57 | CN¥50 |
| Sales & Mktg Exp. | CN¥0 | CN¥16 | CN¥14 | CN¥14 |
| Other Operating Expenses | CN¥65 | -CN¥63 | -CN¥18 | -CN¥154 |
| Operating Expenses | CN¥188 | CN¥63 | CN¥99 | -CN¥39 |
| Operating Income | CN¥131 | CN¥184 | CN¥162 | CN¥162 |
| % Margin | 15% | 20.6% | 20.8% | 21.9% |
| Other Income/Exp. Net | CN¥30 | -CN¥0 | -CN¥4 | -CN¥2 |
| Pre-Tax Income | CN¥161 | CN¥184 | CN¥158 | CN¥161 |
| Tax Expense | CN¥23 | CN¥24 | CN¥34 | CN¥24 |
| Net Income | CN¥142 | CN¥172 | CN¥137 | CN¥144 |
| % Margin | 16.2% | 19.2% | 17.7% | 19.4% |
| EPS | 0.2 | 0.24 | 0.23 | 0.25 |
| % Growth | -16.7% | 4.3% | -8% | – |
| EPS Diluted | 0.2 | 0.24 | 0.23 | 0.25 |
| Weighted Avg Shares Out | 719 | 719 | 595 | 582 |
| Weighted Avg Shares Out Dil | 719 | 719 | 595 | 582 |
| Supplemental Information | – | – | – | – |
| Interest Income | CN¥48 | CN¥67 | CN¥31 | CN¥43 |
| Interest Expense | CN¥1 | CN¥1 | CN¥7 | CN¥5 |
| Depreciation & Amortization | CN¥0 | CN¥78 | CN¥79 | CN¥79 |
| EBITDA | CN¥164 | CN¥187 | CN¥222 | CN¥73 |
| % Margin | 18.8% | 20.9% | 28.6% | 9.8% |